drugset / Trial / NCT07013851
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Phase 2
Not yet recruiting
25 enrolled
Spanish Ovarian Cancer Research Group
GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer. The study is conducted in Spain with an estimated number of 25 patients for phase II. The main objective of this phase-II study is to evaluate the clinical complete response (cCR) after neoadjuvant therapy with dostarlimab.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2029-03-01
- Completion
- 2029-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | 500 mg | — |
| Subject | Dostarlimab | Monoclonal antibody | 1000 mg | — |